observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

1 week ago

HelloFresh Reaffirms Commitment to Fighting Food Insecurity During Hunger Action Month

HelloFresh and its partners celebrate 10 million meals donated through Meals with Meaning, a program launched in 2020.NEW YORK--(BUSINESS WIRE)--This…

2 weeks ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

June 21, 2025 18:00 ET  | Source: BioAge Labs, Inc. Treatment with apelin receptor agonist enhanced glycemic control and demonstrated…

3 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

4 months ago